


---

Erratum

In the article by Roberts et al entitled “The use of recombinant factor VIIa in the treatment of bleeding disorders,” which appeared in the December 15, 2004, issue of Blood (Volume 104:3858-3864), the following disclosure was inadvertently omitted by the journal: H.R.R. has been a consultant for and has received an honorarium from Novo Nordisk, the manufacturer of recombinant factor VIIa. He is also a consultant to Baxter Bioscience, which manufactures a competing product, and he has received honoraria from Bayer. G.C.W. is a consultant for and has received honoraria from Baxter Bioscience, Bayer, and Novo Nordisk.
Erratum for vol. 104, p. 3858

Updated information and services can be found at:
http://www.bloodjournal.org/content/105/6/2257.full.html
Articles on similar topics can be found in the following Blood collections

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml